Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic?

A type 1 diabetes patient experienced remission associated with chloroquine therapy while travelling to a malaria-endemic area. Chloroquine has immunomodulatory and hypoglycaemic effects and may become more frequently used due to the COVID-19 pandemic. Patients with type 1 diabetes treated with chlo...

Descripción completa

Detalles Bibliográficos
Autor principal: Baretić, Maja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Diabetes India. Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153521/
https://www.ncbi.nlm.nih.gov/pubmed/32315948
http://dx.doi.org/10.1016/j.dsx.2020.04.014
Descripción
Sumario:A type 1 diabetes patient experienced remission associated with chloroquine therapy while travelling to a malaria-endemic area. Chloroquine has immunomodulatory and hypoglycaemic effects and may become more frequently used due to the COVID-19 pandemic. Patients with type 1 diabetes treated with chloroquine should be monitored for hypoglycaemia, even after recovery.

Ejemplares similares